{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DHR",
  "name": "Danaher Corporation",
  "url": "https://frontierpicks.com/dossiers/DHR/",
  "json_url": "https://frontierpicks.com/dossiers/DHR.json",
  "status": "HELD",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "Danaher's bioprocessing recovery is driving faster profit growth, with mid-teens order growth and raised 2026 guidance on 21 October 2026; its January 2027 report, with formal 2027 guidance, settles whether revenue follows.",
  "invalidation_trigger": "A daily close below $210, which would undo the post-report rerating behind the $254–$270 broker targets; or formal 2027 guidance in January for core growth excluding respiratory below 4%.",
  "catalyst_date": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Danaher reports total core growth and core growth excluding respiratory testing separately; Cepheid respiratory revenue swings with flu and COVID seasons.",
    "Results from the Masimo acquisition, closed 2026-06-10, are included in the Diagnostics segment from that date, which lifts reported growth above core growth."
  ],
  "body_markdown": "## Current Thesis\n\nDanaher's bioprocessing business is recovering and its earnings are growing faster than revenue. Third-quarter 2026 bioprocessing orders rose in the mid-teens, and full-year profit guidance went up on 2026-10-21. What settles the case is the formal 2027 guidance in the late-January fourth-quarter report. Management called 4% to 5% core growth excluding respiratory testing \"a reasonable starting point\" for 2027. The view is that the shares can keep pace with or beat the S&P 500 while orders keep turning into revenue.\n\nThe narrative is maturing. Eight brokers raised their targets within two days of the 2026-10-21 report, and the shares closed at $232.97 on 2026-10-26, 3.2% below their 52-week high of $240.59. Most of the recovery from the July sell-off has already happened. Further gains now depend on delivery, because the story itself is no longer new.\n\n## Bull Case\n\n- Adjusted operating margin rose 110 basis points to 29%.\n- **Bioprocessing orders running ahead of revenue.** Management said on the 2026-10-21 call that bioprocessing orders rose in the mid-teens, led by upstream consumables. Revenue grew toward the upper end of mid-single digits. Orders running ahead of sales point to revenue growth in coming quarters.\n- **Guidance raised for the full year.** The 2026 adjusted EPS range moved to $8.57–$8.62 from $8.45–$8.60, according to the company's 2026-10-21 release.\n- **Strong cash generation.** Free cash flow was $1,632 million in the third quarter, up about 19%, per the 8-K.\n- **Analyst targets moved up together.** On 2026-10-22, Citi, JPMorgan and TD Cowen set $270 targets, Barclays and Stifel set $260, and Baird set $254. RBC raised its target to $265 on 2026-10-21, and HSBC moved from $250 to $260 on 2026-10-23.\n- **Masimo adds growth in Diagnostics.** Danaher closed the $9.9 billion Masimo acquisition on 2026-06-10. Management said Masimo grew revenue at a high-single-digit rate in its first full quarter inside Danaher.\n\n## Bear Case\n\n- **Respiratory testing is still shrinking.** Respiratory revenue at Cepheid was about $350 million in the third quarter and fell year over year. It held total core growth to 3.0%, against 5.5% excluding respiratory, per the 8-K. Diagnostics core growth was 0.5%.\n- **The 2027 outlook is only a starting point.** Formal guidance comes in January. TD Cowen cited tariffs and a cautious 2027 outlook when it raised its target on 2026-10-22, according to Benzinga.\n- **Bioprocessing timing has already disappointed once.** On 2026-07-21, customers pushed more than $100 million of bioprocessing shipments, mostly chromatography resins, into 2027, and the shares fell by double digits that day, according to TIKR. If another round of delays came, it would hit the same part of the case.\n- **Reshoring revenue comes later.** Management sized United States bioprocessing reshoring at about $1 billion, but expects the larger revenue impact to begin in 2028, per the 2026-10-21 call.\n- **A new CEO is still setting priorities.** Julie Sawyer Montgomery became chief executive on 2026-10-01. On her first call she stressed execution and innovation, and said acquisitions remain the preferred use of capital.\n\n## Setup & Price Structure\n\nThe shares closed at $232.97 on 2026-10-26, based on adjusted daily closes. That is 3.2% below the 52-week high of $240.59 and 18.8% above the close three months earlier. The 14-day relative strength index (RSI) reads 70.6, the threshold usually taken as overbought. The shares fell 1.8% the day after the beat, according to Benzinga, so the October rally came before the report and continued after it.\n\nCrowding signs are momentum-driven. The gain is steep, the RSI is stretched and the price is close to its high. The brokers' raised targets cluster between $254 and $270. No insider sales or share issuance accompanied the rally in the company news reviewed.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-10-27 to 2026-11-26:** Danaher has no confirmed company event in this window. The shares will mostly follow life-science tools peers and early respiratory-season infection rates. Fourth-quarter guidance assumes respiratory is about a 150-basis-point headwind to core growth.\n- **~2027-01-27 (est.):** The fourth-quarter 2026 report and formal 2027 guidance. This is the event that tests the 4%–5% starting point and the strength of bioprocessing orders. It falls near the end of the three-month window.\n\n## What Would Change Our Mind\n\nThe case breaks if bioprocessing orders stop leading revenue. Signs of that would be another round of customer shipment delays, or management describing orders as flat in the January report. The case also breaks if formal 2027 guidance for core growth excluding respiratory comes in below 4%.\n\nOn price, a daily close below $210 would mean the market has rejected the post-report rerating. That would contradict the brokers' $254–$270 target range.\n\n## Correlation Notes\n\nDanaher's bioprocessing unit sells consumables and equipment for making biologic drugs. That makes the shares sensitive to biopharma production volumes and capital spending, so they tend to trade with other life-science tools suppliers. The Diagnostics segment adds exposure to flu and COVID testing seasons through Cepheid. It also adds hospital patient monitoring through Masimo, which moves on different drivers. Tariff policy affects the shares through costs and refunds: the company's latest 10-Q put the net tariff refund benefit under $100 million and called the outlook uncertain.",
  "first_seen": "2026-10-26",
  "last_analyzed": "2026-10-27T03:32:07+00:00",
  "last_synthesized": "2026-10-27",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}